Pharmaceuticals and Healthcare

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib

China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.

Aptar unveils framework for injectable drug delivery systems

Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems.

JCVI issues recommendation on adolescent MenB vaccination in UK

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine programme with the 4CMenB vaccine for adolescents.

FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN

The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).

Piramal Pharma opens oral solid dosage suite in Pennsylvania, US

Piramal Pharma Solutions and NewAmsterdam Pharma have announced the inauguration of an oral solid dosage (OSD) suite at the former’s facility located in Sellersville, Pennsylvania, US.

FDA issues CRL to PharmaTher’s ketamine ANDA

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to PharmaTher concerning its ketamine abbreviated new drug application (ANDA).

RTI partners with Codetta Bio to boost healthcare innovation

RTI International has announced a strategic collaboration with Codetta Bio, a company specialising in multi-omics for precision medicine development, to fast-track healthcare innovation.

AstraZeneca targets $80bn revenue by 2030

AstraZeneca has announced an ambitious target to deliver total revenue of $80bn by 2030, an increase from $45.8bn in 2023.